Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2008-01-15
2008-01-15
Kim, Young J. (Department: 1637)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
Reexamination Certificate
active
10867578
ABSTRACT:
The present invention relates to methods and kits for determining a predisposition for developing cancer, e.g., prostate and/or breast cancer, due to a germline mutation of a NBS1 gene. The present invention also relates to surveillance protocols for developing cancer, e.g., prostate and/or breast cancer, due to germline mutation of a NBS1 gene.
REFERENCES:
patent: 6458534 (2002-10-01), Concannon et al.
Printout: (The Scientist (2004) vol. 18).
Stumm et al. (“No evidence for deletions of the NBS1 gene in lymphomas” Cancer Genet Cytogenet. Apr. 1, 2001;126(1):60-2).
Carlomango et al. (“Determination of the frequency of the common 657Del5 Nimegen breakage syndrome mutation in the German population: no association with risk of breast cancer” Genes Chromosomes Cancer. Aug. 1999;25(4):393-5).
Varon et al. (“Clinical ascertainment of Nijmegen breakage syndrome (NBS) and prevalence of the major mutation, 657del5, in three Slav populations” Eur J Hum Genet. Nov. 2000;8(11):900-2).
Carney, James P., et al., “The hMre11/hRad50 protein complex and Nijmegen breakage syndrome: linkage of double-strand break repair to the cellular DNA damage response”,Cell, 93(3), (May 1, 1998), 477-486.
Carpten, J., et al., “Germline mutations in the ribonuclease L gene in families showing linkage with HPC1”,Nature Genetics, 30(2), (Feb. 2002), 181-184.
Cybulski, C., et al., “CHEK2 Is a Multiorgan Cancer Susceptibility Gene”,Am. J. Hum. Genet., vol. 75, (2004), 1131-1135.
Cybulski, C., et al., “NBS1 is a prostate cancer suseptibility gene”,Cancer Research, 64(4), (Feb. 15, 2004), 1215-1219.
Debniak, Tadeusz, “Germline 657del5 mutation in the NBS1 gene in patients with malignant melanoma of the skin”,Melanoma Research, 13, (2003), 365-370.
Digweed, M., “Human genetic instability syndromes: single gene defects with increased risk of cancer”,Toxicol Lett., 67(1-3), Apr. 1993), 259-81.
Dong, Xiangyang, et al., “Mutations in CHEK2 Associated with Prostate Cancer Risk”,Am. J. Hum. Genet., vol. 72, (2003), 270-280.
Fan, Zuoheng, et al., “Adenovirus-mediated antisense ATM gene transfer sensitizes prostate cancer cells to radiation”,Cancer Gene Therapy, vol. 7, (2000), 1307-1314.
Futaki, Makoto, “Chromosomal breakage syndromes and the BRCA1 genome surveillance complex”,Trend in Molecular Medicine, 7 (12), (Dec. 2001), 560-565.
Gayther, Simon A., et al., “The frequency of germ-line mutations in the breast cancer predisposition genes BRCA1 and BRCA2 in familial prostate cancer. The Cancer Research Campaign/British Prostate Group United Kingdom Familial Prostate Cancer Study Collaborators”,Cancer Research, 60(16), (Aug. 15, 2000), 4513-4518.
Gorski, Bohdan, et al., “Germline 657del5 Mutation in the NBS1 Gene in Breast Cancer Patients”,Int. J. Cancer, 106 (2003), 379-381.
Koivisto, Pasi A., et al., “Amplification of the Androgen Receptor Gene is Associated with P53 Mutation in Hormone-Refactory Recurrent Prostate Cancer”,Journal of Pathology, vol. 187, (1999), 237-241.
Lichtenstein, Paul, et al., “Environmental and Heritable Factors in the Causation of Cancer”,The New England Journal of Medicine, 343(2), (Jul. 13, 2000), 78-85.
Matsuura, Shinya, et al., “Positional cloning of the gene for Nijmegen breakage syndrome”,Nature Genetics, 19, (Jun. 1998), 179-181.
Plisiecka-Halasa, J., “Nijmegen breakage syndrome gene (NBS.1) alterations and its protein (nibrin) expression in human ovarian tumours”,Ann. Hum. Genet., vol. 66, (2002), 353-359.
Rebbeck, Timothy R., et al., “Association of HPC2/ELAC2 Genotypes and Prostate Cancer”,Am. J. Hum. Genet., vol. 67, (2000), 1014-1019.
Seemanova, E., “An increased risk for malignant neoplasms in heterozygotes for a syndrome of mycrocephaly, normal intelligence, growth retardation, remarkable facies, immunodeficiency and chromosomal instability”,Mutation Research, 238 (1990), 321-324.
Steffen, J., et al., “Frequency of the heterozygous germline NBS1 mutation 657del5 in cancer patients from Poland”,Casopis Lekaru Ceskych, 141(8), International Workshop on Nijmegen Breakage Syndrome, Prague, Czech Republic, (2002), VII-VIII.
Steffen, Jan, et al., “Increased Cancer risk of Heterozygotes with NBS1 Germline Mutation in Poland”,Int. J. Cancer., vol. 111, (2004), 67-71.
Tavtigian, Sean V., et al., “A candidate prostate cancer susceptibility gene at chromosome 17p”,Nature Genetics, 27, (Feb. 2001), 172-180.
Van Der Burgt, Ineke, et al., “Nijmegen breakage syndrome”,J. Med. Genet, 22(2), (Feb. 1996), 153-156.
Varon, Raymonda, “Clinical ascertainment of Nijmegen breakage syndrome (NBS) and prevalence of the major mutation, 657del5 in three Slav populations”,European Journal of Human Genetics, vol. 8, (200), 900-902.
Varon, Raymonda, “Mutations in the Nijmegen Breakage Syndrome Gene (NBS1) in Childhood Acute Lymphoblastic Leukemia (ALL)”,Cancer Research, vol. 61, (May 1, 2001), 3570-3572.
Varon, Raymonda, “Nibrin, a Novel Double-Strand Break Repair Protein, Is Mutated in Nijmegen Breakage Syndrome”,Cell, vol. 93,, (May 1, 1998), 467-476.
Voelkel-Johnson, Christina , et al., “Genomic instability-based transgenic models of prostate cancer”,Carcinogenesis, 21(8), (2000), 1623-1627.
Wang, Liang, et al., “Role of HPC2/ELAC2 in Hereditary Prostate Cancer1”,Cancer Research, vol. 61, (Sep. 1, 2001), 6494-6499.
Xu, J., et al., “Evaluation of linkage and association of HPC2/ELAC2 in patients with familial or spordic prostate cancer”,Am J Hum Genet., 68(4), (Apr. 2001), 901-11.
Xu, Jianfeng, et al., “Genomewide Screen and Identification of Gene-Gene Interactions for Asthma-Susceptibility Loci in Three U.S. Populations: Collaboratice Study on the Genetics of Asthma”,American Journal of Human Genetics, 68, (Jun. 2001), 1437-1446.
Byrski Tomasz
Cybulski Cezary
Debniak Tadeusz
Gliniewicz Bartlomiej
Gorski Bohdan
Babic Christopher M.
Cooper & Dunham LLP
Gershik Gary J.
Kim Young J.
Pomeranian Academy of Medicine
LandOfFree
Determining a predisposition to cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Determining a predisposition to cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Determining a predisposition to cancer will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3908510